1. Home
  2. BOW vs ARVN Comparison

BOW vs ARVN Comparison

Compare BOW & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$28.70

Market Cap

913.3M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$12.11

Market Cap

806.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOW
ARVN
Founded
2020
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.3M
806.0M
IPO Year
2024
2018

Fundamental Metrics

Financial Performance
Metric
BOW
ARVN
Price
$28.70
$12.11
Analyst Decision
Buy
Buy
Analyst Count
6
23
Target Price
$36.00
$17.89
AVG Volume (30 Days)
195.9K
1.1M
Earning Date
11-04-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
42.10
N/A
EPS
1.53
N/A
Revenue
$519,241,000.00
$312,300,000.00
Revenue This Year
$16.05
$11.06
Revenue Next Year
$25.43
N/A
P/E Ratio
$18.76
N/A
Revenue Growth
33.44
93.86
52 Week Low
$23.50
$5.90
52 Week High
$42.29
$21.00

Technical Indicators

Market Signals
Indicator
BOW
ARVN
Relative Strength Index (RSI) 59.62 53.36
Support Level $27.97 $11.20
Resistance Level $28.95 $12.50
Average True Range (ATR) 0.86 0.53
MACD 0.15 -0.14
Stochastic Oscillator 85.88 41.10

Price Performance

Historical Comparison
BOW
ARVN

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Share on Social Networks: